Next-Generation Sequencing-Based Molecular Profiling and Management of Advanced Solid Tumors: A Real-World Experience in a Community-Based Academic Cancer Center.

Authors

Gayathri Moorthy, Annette Sereika, Karen Kaul, Megan Parilla, Mir B Alikhan, Michael Bouma, Dyson Wake, Peter J Hulick, Henry M Dunnenberger, Linda M Sabatini, Mathew Yang, Kathy A Mangold, Erin Proctor, Nicholas Evans, Nicholas Miller, Donald L Helseth, Darryck Maurer, Justin Brueck, Janardan Khandekar, Bruce Brockstein

Published in

Cancer medicine. Volume 15. Issue 10. Pages e72355.

Abstract

Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next-generation sequencing (NGS) at our community-based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine therapy options in patients with advanced solid tumors for whom standard therapies had been exhausted.
Through a prospective non-randomized trial, patients with advanced solid tumors who had exhausted standard therapies and who did not qualify for routine guideline-concordant NGS at the time of the study (the study excluded at least Stage 1B lung and Stage IV colorectal cancers) underwent in-house NGS on tumor specimens to identify actionable alterations, and pharmacogenomic testing. Our in-house-developed/integrated bioinformatics pipeline (Flype) was used for structured reporting and served as a molecular knowledgebase. Patients were presented at a multidisciplinary molecular tumor board.
251 patients underwent somatic tissue NGS. 173 patients (68.9%) had alterations targetable with FDA-approved or currently investigational drugs. 75 patients (29.9%) had alteration(s) qualifying them for FDA-approved drug(s) for their tumor type. An additional 61 patients (24.3%) had alterations qualifying them for "off-label" use of FDA-approved drugs. 40 patients (15.9%) qualified for tumor-agnostic therapies. Of the 224 patients (89.2%) who had RNA analysis, eight (3.6%) had targetable fusions. Of the 33 patients (19.1%) who received NGS-guided targeted therapies, 19 (57.6%) were on treatment for longer than three months. 255 patients underwent pharmacogenomics testing, with over 40% having an alteration in typical response to opioids or antidepressants.
In this real-world study, 54.2% of patients with advanced solid tumors were identified as candidates for FDA-approved therapies (on- or off-label), supporting the utility of in-house NGS in providing genomics-guided care for patients.

PMID:
42839555
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.